选择正确的抗高血压药物以避免静脉透析性低血压
Carmine Zoccali1,2,3, Giovanni Tripepi4, Francesca Mallamaci3
1Renal Research Institute, New York, NY, USA.
Clinical kidney journal
|December 15, 2025
概括
抗高血压药物可以增加血液透析 (HD) 患者内透析性低血压 (IDH) 的风险. 仔细选择药物对于控制血压而最大限度地减少IDH并发症至关重要.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 心脏病学 心脏病学
- 临床药理学 临床药理学
背景情况:
- 静脉透析性低血压 (IDH) 是血液透析 (HD) 患者的常见和严重并发症.
- 抗高血压药物,虽然对于管理高血压是必要的,但可以矛盾地增加IDH的风险和严重程度.
- 了解各种抗高血压药物类别对IDH的不同影响,对于患者的安全性和治疗疗效至关重要.
研究的目的:
- 审查不同类型的抗高血压药物对血液透析 (HD) 患者内透析性低血压 (IDH) 风险的比较影响.
- 评估从观察性研究和目标试验模拟中获得的证据,以评估HD中抗高血压药物的风险.
- 指导临床医生优化抗高血压疗法,以平衡血压控制和尽量减少IDH.
主要方法:
- 对血液透析患者的抗高血压药物及其与IDH相关的文献的系统审查.
- 对β-阻断剂,α-β阻断剂,ACE抑制剂,血管新生素II抗剂,利尿剂和抗剂所带来的差异性风险的分析.
- 讨论一项目标试验仿真研究,以利用观察数据提供对比药物风险的见解.
主要成果:
- 由于对心率和收缩能力的影响,β和α-β抑制剂与IDH的更高风险有关.
- ACE 抑制剂和血管激素II 抗剂可能通过降低血管抵抗来增加 IDH 风险.
- 利尿剂可以在超过过程中加剧体积耗尽,而抗体在一些研究中显示可能降低IDH风险.
结论:
- 抗高血压药物选择显著影响血液透析患者的IDH风险.
- 个性化治疗策略是必不可少的,考虑到特定的药物类效应和患者因素.
- 需要进一步进行高质量的研究,包括随机对照试验,以验证发现并评估长期的心血管结果.
相关概念视频
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.2K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.2K
01:16Antihypertensive Drugs: Action of Diuretics
2.2K
Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
2.2K
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
2.2K
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
2.2K
01:22Heart Failure Drugs: Diuretics
764
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
764
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
879
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
879
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
575
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
575